Literature DB >> 30991144

Antibody-cytokine fusion proteins: A novel class of biopharmaceuticals for the therapy of cancer and of chronic inflammation.

Patrizia Murer1, Dario Neri2.   

Abstract

Antibody-cytokine fusion proteins represent a novel class of biopharmaceuticals, with the potential to increase the therapeutic index of cytokine 'payloads' and to promote leukocyte infiltration at the site of disease. In this review, we present a survey of immunocytokines that have been used in preclinical models of cancer and in clinical trials. In particular, we highlight how antibody format, choice of target antigen and cytokine engineering, as well as combination strategies, may have a profound impact on therapeutic performance. Moreover, by using anti-inflammatory cytokines, antibody fusion strategies can conveniently be employed for the treatment of auto-immune and chronic inflammatory conditions.
Copyright © 2019. Published by Elsevier B.V.

Entities:  

Keywords:  Antibody-fusion proeins; Cancer; Chronic inflammation; Cytokines; Immunemodulation; Immunocytokines; Immunotherapy; Targeted delivery

Mesh：

Substances：

Year:  2019        PMID： 30991144      PMCID： PMC6994257          DOI： 10.1016/j.nbt.2019.04.002

Source DB:  PubMed          Journal:  N Biotechnol        ISSN： 1871-6784            Impact factor:   5.079


  189 in total

1.  Rapid tumor penetration of a single-chain Fv and comparison with other immunoglobulin forms.

Authors:  T Yokota; D E Milenic; M Whitlow; J Schlom
Journal:  Cancer Res       Date:  1992-06-15       Impact factor: 12.701

Review 2.  IL-2: the first effective immunotherapy for human cancer.

Authors:  Steven A Rosenberg
Journal:  J Immunol       Date:  2014-06-15       Impact factor: 5.422

3.  A recombinant IgG3-(IL-2) fusion protein for the treatment of human HER2/neu expressing tumors.

Authors:  M L Penichet; J S Dela Cruz; S U Shin; S L Morrison
Journal:  Hum Antibodies       Date:  2001

4.  Improving the efficacy of antibody-interleukin 2 fusion proteins by reducing their interaction with Fc receptors.

Authors:  S D Gillies; Y Lan; K M Lo; M Super; J Wesolowski
Journal:  Cancer Res       Date:  1999-05-01       Impact factor: 12.701

5.  Synergistic therapeutic effects of a tumor targeting antibody fragment, fused to interleukin 12 and to tumor necrosis factor alpha.

Authors:  Cornelia Halin; Verena Gafner; Maria Elena Villani; Laura Borsi; Alexander Berndt; Hartwig Kosmehl; Luciano Zardi; Dario Neri
Journal:  Cancer Res       Date:  2003-06-15       Impact factor: 12.701

6.  An antimelanoma immunotoxin containing recombinant human tumor necrosis factor: tissue disposition, pharmacokinetic, and therapeutic studies in xenograft models.

Authors:  M G Rosenblum; L Cheung; K Mujoo; J L Murray
Journal:  Cancer Immunol Immunother       Date:  1995-05       Impact factor: 6.968

7.  A recombinant single-chain antibody interleukin-2 fusion protein.

Authors:  P Savage; A So; R A Spooner; A A Epenetos
Journal:  Cell Biophys       Date:  1993 Jan-Jun

Review 8.  Antibody-cytokine fusion proteins: Biopharmaceuticals with immunomodulatory properties for cancer therapy.

Authors:  Cornelia Hutmacher; Dario Neri
Journal:  Adv Drug Deliv Rev       Date:  2018-09-07       Impact factor: 15.470

9.  Antibody-mediated delivery of IL-10 inhibits the progression of established collagen-induced arthritis.

Authors:  Eveline Trachsel; Frank Bootz; Michela Silacci; Manuela Kaspar; Hartwig Kosmehl; Dario Neri
Journal:  Arthritis Res Ther       Date:  2007       Impact factor: 5.156

10.  89Zr-labeled CEA-targeted IL-2 variant immunocytokine in patients with solid tumors: CEA-mediated tumor accumulation and role of IL-2 receptor-binding.

Authors:  Emilie M J van Brummelen; Marc C Huisman; Linda J de Wit-van der Veen; Tapan K Nayak; Marcel P M Stokkel; Emma R Mulder; Otto S Hoekstra; Danielle J Vugts; Guus A M S Van Dongen; Henk M Verheul; Stefan Evers; Jean J L Tessier; Jose Saro; Jan H M Schellens; C Willemien Menke-van der Houven van Oordt
Journal:  Oncotarget       Date:  2018-05-15
View more
  16 in total

1.  An engineered 4-1BBL fusion protein with "activity on demand".

Authors:  Jacqueline Mock; Marco Stringhini; Alessandra Villa; Michael Weller; Tobias Weiss; Dario Neri
Journal:  Proc Natl Acad Sci U S A       Date:  2020-11-25       Impact factor: 11.205

Review 2.  The JAK/STAT signaling pathway: from bench to clinic.

Authors:  Xiaoyi Hu; Jing Li; Maorong Fu; Xia Zhao; Wei Wang
Journal:  Signal Transduct Target Ther       Date:  2021-11-26

Review 3.  Local delivery strategies to restore immune homeostasis in the context of inflammation.

Authors:  Elizabeth R Bentley; Steven R Little
Journal:  Adv Drug Deliv Rev       Date:  2021-09-13       Impact factor: 15.470

Review 4.  Engineered antibody fusion proteins for targeted disease therapy.

Authors:  Aliyah B Silver; Elissa K Leonard; Joseph R Gould; Jamie B Spangler
Journal:  Trends Pharmacol Sci       Date:  2021-10-25       Impact factor: 14.819

5.  89Zr-ImmunoPET Shows Therapeutic Efficacy of Anti-CD20-IFNα Fusion Protein in a Murine B-cell Lymphoma Model.

Authors:  Kirstin A Zettlitz; Felix B Salazar; Reiko E Yamada; K Ryan Trinh; Alex Vasuthasawat; John M Timmerman; Sherie L Morrison; Anna M Wu
Journal:  Mol Cancer Ther       Date:  2022-04-01       Impact factor: 6.009

6.  Development of IL-15/IL-15Rα sushi domain-IgG4 Fc complexes in Pichia pastoris with potent activities and prolonged half-lives.

Authors:  Huan Xu; Mingyang Shi; Changsheng Shao; Hao Li; Jing Wu; Yin Yu; Fang Fang; Yugang Guo; Weihua Xiao
Journal:  Microb Cell Fact       Date:  2021-06-09       Impact factor: 5.328

Review 7.  The use of supercytokines, immunocytokines, engager cytokines, and other synthetic cytokines in immunotherapy.

Authors:  Xiaohu Zheng; Yaqi Wu; Jiacheng Bi; Yingying Huang; Ying Cheng; Yangyang Li; Yuwei Wu; Guoshuai Cao; Zhigang Tian
Journal:  Cell Mol Immunol       Date:  2022-01-04       Impact factor: 11.530

8.  Protein-Antibody Conjugates (PACs): A Plug-and-Play Strategy for Covalent Conjugation and Targeted Intracellular Delivery of Pristine Proteins.

Authors:  Bin Liu; Khushboo Singh; Shuai Gong; Mine Canakci; Barbara A Osborne; S Thayumanavan
Journal:  Angew Chem Int Ed Engl       Date:  2021-05-05       Impact factor: 16.823

Review 9.  Cell-Type Targeted NF-kappaB Inhibition for the Treatment of Inflammatory Diseases.

Authors:  Bettina Sehnert; Harald Burkhardt; Stefan Dübel; Reinhard E Voll
Journal:  Cells       Date:  2020-07-06       Impact factor: 6.600

Review 10.  Targeting the extracellular matrix for immunomodulation: applications in drug delivery and cell therapies.

Authors:  Samira Aghlara-Fotovat; Amanda Nash; Boram Kim; Robert Krencik; Omid Veiseh
Journal:  Drug Deliv Transl Res       Date:  2021-06-26       Impact factor: 4.617
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.